Literature DB >> 604196

Humoral immune system in inflammatory bowel disease: I. Complement levels.

H J Hodgson, B J Potter, D P Jewell.   

Abstract

Serum levels of complement components Clq, C4, C3, and Properdin factor B, from the classical and alternative pathways of complement activation, have been estimated in patients with ulcerative colitis and Crohn's disease. C3, factor B, and to some extent C4 concentrations all increased when the disease was active. In remission the levels of these components did not differ from hospital control patients. There was no evidence for the preferential consumption of the proteins of either pathway of activation, even in those patients with evidence of circulating immune complexes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 604196      PMCID: PMC1411653          DOI: 10.1136/gut.18.9.749

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  The alternate complement pathway in inflammatory bowel disease. Quantitation of the C3 proactivator (factor B) protein.

Authors:  P A Feinstein; S R Kaplan; W R Thayer
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Plasma protein pattern in acute infectious diseases.

Authors:  K Ganrot
Journal:  Scand J Clin Lab Invest       Date:  1974-09       Impact factor: 1.713

4.  Evidence for complement-binding immune complexes in adult coeliac disease, Crohn's disease, and ulcerative colitis.

Authors:  W F Doe; C C Booth; D L Brown
Journal:  Lancet       Date:  1973-02-24       Impact factor: 79.321

5.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

6.  Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus.

Authors:  P F Kohler; R Ten Bensel
Journal:  Clin Exp Immunol       Date:  1969-02       Impact factor: 4.330

7.  Proceedings: Serum complement components C3 and C4 in inflammatory bowel disease.

Authors:  M Ward; M A Eastwood
Journal:  Gut       Date:  1974-10       Impact factor: 23.059

8.  High levels of serum complement factors in juvenille rheumatoid arthritis.

Authors:  H M Höyeraal; O J Mellbye
Journal:  Ann Rheum Dis       Date:  1974-05       Impact factor: 19.103

9.  Serum complement in chronic liver disease.

Authors:  B J Potter; A M Trueman; E A Jones
Journal:  Gut       Date:  1973-06       Impact factor: 23.059

10.  Interactions of the complement system with endotoxic lipopolysaccharide: consumption of each of the six terminal complement components.

Authors:  H Gewurz; H S Shin; S E Mergenhagen
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  16 in total

1.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Serum bactericidal resistance of faecal Escherichia coli and bactericidal competence of serum from patients with ulcerative colitis.

Authors:  D A Burke; S A Clayden; A T Axon
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

3.  Defective release of C5a related chemo-attractant activity from complement in Crohn's disease.

Authors:  J Elmgreen; A Berkowicz; H Sørensen
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

Review 4.  Assessment of drug therapy in inflammatory bowel disease.

Authors:  H J Hodgson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

5.  Circulating immune complexes in Crohn's disease. Their characterization and interrelationship with components of the complement system.

Authors:  E R Richens; C M Thorp; P W Bland; N D Hall
Journal:  Dig Dis Sci       Date:  1982-02       Impact factor: 3.199

6.  Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

Authors:  B J Potter; D J Brown; A Watson; D P Jewell
Journal:  Gut       Date:  1980-12       Impact factor: 23.059

7.  A cross-ethnic survey of CFB and SLC44A4, Indian ulcerative colitis GWAS hits, underscores their potential role in disease susceptibility.

Authors:  Aditi Gupta; Garima Juyal; Ajit Sood; Vandana Midha; Keiko Yamazaki; Arnau Vich Vila; Motohiro Esaki; Toshiyuki Matsui; Atsushi Takahashi; Michiaki Kubo; Rinse K Weersma; B K Thelma
Journal:  Eur J Hum Genet       Date:  2016-10-19       Impact factor: 4.246

8.  The humoral immune system in inflammatory bowel disease. II. Immunologlobulin levels.

Authors:  H J Hodgson; D P Jewell
Journal:  Am J Dig Dis       Date:  1978-02

9.  In vitro studies on cellular and humoral chemotaxis in Crohn's disease using the under agarose gel technique.

Authors:  R D'Amelio; P Rossi; S Le Moli; R Ricci; S Montano; F Pallone
Journal:  Gut       Date:  1981-07       Impact factor: 23.059

10.  Hyperthyroidism and ulcerative colitis: report of two cases and a review of the literature.

Authors:  S K Iyer; R G Karlstadt
Journal:  J Natl Med Assoc       Date:  1980-02       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.